JAMA (Journal of the American Medical Association)
رفتن به کانال در Telegram
All the latest articles published on JAMA before going in to print Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot
نمایش بیشتر📈 تحلیل کانال تلگرام JAMA (Journal of the American Medical Association)
کانال JAMA (Journal of the American Medical Association) (@jamaupdates) در بخش زبانی انگلیسی بازیگری فعال است. در حال حاضر جامعه شامل 16 369 مشترک است و جایگاه 1 462 را در دسته پزشکی و رتبه 2 277 را در منطقه الولايات المتحدة الأمريكية دارد.
📊 شاخصهای مخاطب و پویایی
از زمان ایجاد در невідомо، پروژه رشد سریعی داشته و 16 369 مشترک جذب کرده است.
بر اساس آخرین دادهها در تاریخ 15 سپتامبر, 2026، کانال فعالیت پایداری دارد. در ۳۰ روز گذشته تغییر اعضا برابر 316 و در ۲۴ ساعت گذشته برابر 15 بوده و همچنان دسترسی گستردهای حفظ شده است.
- وضعیت تأیید: تأیید نشده
- نرخ تعامل (ER): میانگین تعامل مخاطب 4.36% است و در ۲۴ ساعت نخست پس از انتشار، محتوا معمولاً 1.90% واکنش نسبت به کل مشترکان کسب میکند.
- دسترسی پستها: هر پست به طور میانگین 713 بازدید دریافت میکند. در اولین روز معمولاً 311 بازدید جمعآوری میشود.
- واکنشها و تعامل: مخاطبان بهطور فعال حمایت میکنند؛ میانگین واکنش به هر پست 1 است.
- علایق موضوعی: محتوا بر موضوعات کلیدی مانند patient, disease, treatment, drug, guideline تمرکز دارد.
📝 توضیح و سیاست محتوایی
نویسنده این فضا را محل بیان دیدگاههای شخصی توصیف میکند:
“All the latest articles published on JAMA before going in to print
Discussion Group
https://t.me/Medical_Professionals_Forum
Contact us
https://t.me/Contact_Updates_in_Medicine_Bot”
به لطف بهروزرسانیهای پرتکرار (آخرین داده در تاریخ 16 سپتامبر, 2026)، کانال همواره بهروز و دارای دسترسی بالاست. تحلیلها نشان میدهد مخاطبان بهطور فعال با محتوا تعامل دارند و آن را به نقطه اثرگذاری مهم در دسته پزشکی تبدیل کردهاند.
16 369
مشترکین
+1524 ساعت
+767 روز
+31630 روز
در حال بارگیری داده...
کانالهای مشابه
ابر برچسبها
اشارات ورودی و خروجی
---
---
---
---
---
---
جذب مشترکین
سپتامبر '26
سپتامبر '26
+150
در 0 کانالها
اوت '26
+361
در 0 کانالها
Get PRO
ژوئیه '26
+440
در 0 کانالها
Get PRO
ژوئن '26
+422
در 0 کانالها
Get PRO
مه '26
+584
در 0 کانالها
Get PRO
آوریل '26
+437
در 0 کانالها
Get PRO
مارس '26
+217
در 0 کانالها
Get PRO
فوریه '26
+247
در 0 کانالها
Get PRO
ژانویه '26
+321
در 0 کانالها
Get PRO
دسامبر '25
+277
در 0 کانالها
Get PRO
نوامبر '25
+366
در 2 کانالها
Get PRO
اکتبر '25
+164
در 0 کانالها
Get PRO
سپتامبر '25
+12
در 0 کانالها
Get PRO
اوت '25
+29
در 0 کانالها
Get PRO
ژوئیه '25
+30
در 0 کانالها
Get PRO
ژوئن '25
+17
در 0 کانالها
Get PRO
مه '25
+9
در 0 کانالها
Get PRO
آوریل '25
+5
در 0 کانالها
Get PRO
مارس '25
+17
در 0 کانالها
Get PRO
فوریه '25
+12
در 0 کانالها
Get PRO
ژانویه '25
+18
در 1 کانالها
Get PRO
دسامبر '24
+237
در 0 کانالها
Get PRO
نوامبر '24
+1 122
در 0 کانالها
Get PRO
اکتبر '24
+1 120
در 0 کانالها
Get PRO
سپتامبر '24
+1 527
در 1 کانالها
Get PRO
اوت '24
+1 128
در 1 کانالها
Get PRO
ژوئیه '24
+1 216
در 0 کانالها
Get PRO
ژوئن '24
+781
در 1 کانالها
Get PRO
مه '24
+797
در 1 کانالها
Get PRO
آوریل '24
+808
در 1 کانالها
Get PRO
مارس '24
+821
در 2 کانالها
Get PRO
فوریه '24
+753
در 1 کانالها
Get PRO
ژانویه '24
+768
در 0 کانالها
Get PRO
دسامبر '23
+716
در 1 کانالها
Get PRO
نوامبر '23
+96
در 1 کانالها
Get PRO
اکتبر '23
+86
در 0 کانالها
Get PRO
سپتامبر '23
+73
در 0 کانالها
Get PRO
اوت '23
+90
در 0 کانالها
Get PRO
ژوئیه '23
+107
در 0 کانالها
Get PRO
ژوئن '23
+105
در 0 کانالها
Get PRO
مه '23
+169
در 0 کانالها
Get PRO
آوریل '23
+128
در 0 کانالها
Get PRO
مارس '23
+84
در 0 کانالها
Get PRO
فوریه '23
+75
در 0 کانالها
Get PRO
ژانویه '23
+71
در 0 کانالها
Get PRO
دسامبر '22
+74
در 0 کانالها
Get PRO
نوامبر '22
+149
در 0 کانالها
Get PRO
اکتبر '22
+90
در 0 کانالها
Get PRO
سپتامبر '22
+138
در 0 کانالها
Get PRO
اوت '22
+77
در 0 کانالها
Get PRO
ژوئیه '22
+50
در 0 کانالها
Get PRO
ژوئن '22
+96
در 0 کانالها
Get PRO
مه '22
+75
در 0 کانالها
Get PRO
آوریل '22
+80
در 0 کانالها
Get PRO
مارس '22
+65
در 0 کانالها
Get PRO
فوریه '22
+26
در 0 کانالها
Get PRO
ژانویه '22
+56
در 0 کانالها
Get PRO
دسامبر '21
+44
در 0 کانالها
Get PRO
نوامبر '21
+39
در 0 کانالها
Get PRO
اکتبر '21
+61
در 0 کانالها
Get PRO
سپتامبر '21
+66
در 0 کانالها
Get PRO
اوت '21
+65
در 0 کانالها
Get PRO
ژوئیه '21
+96
در 0 کانالها
Get PRO
ژوئن '21
+120
در 0 کانالها
Get PRO
مه '21
+130
در 0 کانالها
Get PRO
آوریل '21
+812
در 0 کانالها
| تاریخ | رشد مشترکین | اشارات | کانالها | |
| 16 سپتامبر | +1 | |||
| 15 سپتامبر | +15 | |||
| 14 سپتامبر | +4 | |||
| 13 سپتامبر | +24 | |||
| 12 سپتامبر | +9 | |||
| 11 سپتامبر | +9 | |||
| 10 سپتامبر | +13 | |||
| 09 سپتامبر | +4 | |||
| 08 سپتامبر | +11 | |||
| 07 سپتامبر | +9 | |||
| 06 سپتامبر | +16 | |||
| 05 سپتامبر | +11 | |||
| 04 سپتامبر | +5 | |||
| 03 سپتامبر | 0 | |||
| 02 سپتامبر | +15 | |||
| 01 سپتامبر | +4 |
پستهای کانال
Caring Collectively Through Palliative Care Partnerships
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2853900
End-of-life cancer care represents a pivotal period for patients, families, and care providers. Palliative care consultation can enhance the quality of end-of-life care for patients with cancer, which has been demonstrated to be beneficial. The palliative care workforce, while growing, is still inadequate to meet patient care needs. Furthermore, the effectiveness of palliative care programs has been inconsistent in prior research, with some programs improving quality of life but not health care utilization. Specifically, hospice utilization varies widely despite the consistent presence of palliative care services in many oncology settings.
| 2 | Administrative Bloat in Neurology and Academic Medicine
https://jamanetwork.com/journals/jamaneurology/fullarticle/2854115
This Viewpoint describes the growth of administrative work across universities, health care, and research and suggests 5 questions a neurology department should ask about any administrative process. | 459 |
| 3 | Clinical Characteristics, Neuroimaging Findings, and Mortality in Korsakoff Syndrome
https://jamanetwork.com/journals/jamaneurology/fullarticle/2854116
This cohort study of French adults diagnosed with Korsakoff syndrome identifies clinical features and outcomes of patients in routine clinical practice and examines factors associated with mortality. | 419 |
| 4 | IVIG in Idiopathic Inflammatory Myopathies
https://jamanetwork.com/journals/jamaneurology/fullarticle/2854117
This randomized clinical trial evaluates the use of intravenous immune globulin as add-on treatment in newly diagnosed idiopathic inflammatory myopathy. | 371 |
| 5 | CAA-Like Brain Imaging and Dural AVF
https://jamanetwork.com/journals/jamaneurology/fullarticle/2854118
This case report describes a patient in their 70s initially diagnosed with cerebral amyloid angiopathy whose diagnosis was challenged with repeat magnetic resonance imaging, which revealed arterialized left temporal cortical vein with an adjacent venous aneurysm. | 360 |
| 6 | Weight Loss in Older Adults With Persistent Atrial Fibrillation
https://jamanetwork.com/journals/jama/fullarticle/2854052
To the Editor In the LOSE-AF randomized clinical trial, a low-calorie diet and behavioral support program achieved significant weight loss but did not improve atrial fibrillation (AF) symptoms, AF burden, or subsequent rhythm-control outcomes in older patients with persistent AF. We believe an imbalance in baseline rhythm-control therapies may have affected the interpretation of these null findings. | 383 |
| 7 | Azithromycin for Cesarean Delivery
https://jamanetwork.com/journals/jama/fullarticle/2854053
Preventing maternal morbidity and mortality remains an urgent global priority, yet progress has been unsatisfactory. Although maternal mortality has declined globally, the rates have increased in the US and infections are among the top causes of preventable deaths. Among women undergoing cesarean delivery (the most common major surgical procedure in the US), the risk of infection is many times higher than after vaginal delivery, underscoring the importance of effective prophylaxis. | 382 |
| 8 | Idiopathic Normal Pressure Hydrocephalus: A Review
https://jamanetwork.com/journals/jama/fullarticle/2854046
This Review discusses the pathophysiology, epidemiology, risk factors, clinical presentation, diagnosis, treatment, and prognosis of idiopathic normal pressure hydrocephalus. | 374 |
| 9 | Error in Results
https://jamanetwork.com/journals/jama/fullarticle/2854054
The Original Investigation titled “Gastric Residual Volume Assessment in Critically Ill Children: The GASTRIC-PICU Randomized Clinical Trial,” published on June 12, 2026, was corrected to update the number of participants in the usual care group in Figure 1 and P values for the intention-to-treat clinical co–primary outcome and per-protocol analysis in the Results section to be consistent with Table 2. This article was corrected online. | 373 |
| 10 | World Trade Center Exposure at 25 Years
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2853739
This Viewpoint discusses how clinicians can screen patients for exposure to the World Trade Center attacks on September 11, 2001. | 657 |
| 11 | Study Finds Artery Damage in Young Adults With CKM Syndrome
https://jamanetwork.com/journals/jama/fullarticle/2854233
Cardiovascular-kidney-metabolic (CKM) syndrome is prevalent among young adults and is associated with greater signs of early artery damage, according to a study published in Circulation: Population Health and Outcomes. Nearly 80% of participants had CKM syndrome stages 1 to 3, which were linked to worse cardiovascular health. | 676 |
| 12 | Nicotine Vapes May Aid in Smoking Cessation
https://jamanetwork.com/journals/jama/fullarticle/2854234
More people may quit smoking when using nicotine e-cigarettes, also known as vapes, compared with conventional nicotine replacement therapies (NRT) such as gum or patches and quitting with or without behavioral support, according to an updated Cochrane review. | 617 |
| 13 | Audio Highlights September 11, 2026
https://jamanetwork.com/journals/jama/fullarticle/2854237
Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA. | 571 |
| 14 | Psilocybin
https://jamanetwork.com/journals/jama/fullarticle/2853938
This JAMA Insights discusses the medical use of psilocybin, particularly for depression treatment, including emerging potential indications, safety, and future use. | 726 |
| 15 | Medicine’s Role in Mental Health Promotion
https://jamanetwork.com/journals/jama/fullarticle/2853937
Dana L. Farnsworth, M.D., Cambridge, Mass. | 664 |
| 16 | Loberamisal for Acute Ischemic Stroke Research Summary
https://jamanetwork.com/journals/jama/fullarticle/2854041
This trial evaluated whether intravenous loberamisal improves functional outcomes and is safe in adults with acute ischemic stroke treated within 48 hours of symptom onset. | 627 |
| 17 | Patient Information: Psilocybin
https://jamanetwork.com/journals/jama/fullarticle/2854042
This JAMA Patient Page describes the psychedelic compound psilocybin, its medical and recreational use, and its potential side effects. | 561 |
| 18 | Loberamisal for Acute Ischemic Stroke
https://jamanetwork.com/journals/jama/fullarticle/2854043
This randomized clinical trial evaluates whether intravenous loberamisal improves functional outcomes and maintains an acceptable safety profile in patients with acute ischemic stroke treated within 48 hours of symptom onset. | 520 |
| 19 | Neuroprotective Therapy for Acute Ischemic Stroke
https://jamanetwork.com/journals/jama/fullarticle/2854044
A remarkable era in acute ischemic stroke care is now coming to a close—the period of the “reperfusion revolution.” Over the past few decades, pharmacological and mechanical flow restoration therapies became steadily more effective. By restoring blood flow and terminating the ischemic period, reperfusion salvages those cerebral tissues not yet irreversibly injured. However, the reperfusion strategy in acute stroke care is now reaching its limits. Current endovascular thrombectomy approaches reopen over 85% of occluded arteries, leaving little scope for further advance. And successful reperfusion treatment alone clearly only partially solves the therapeutic challenge. Among patients with ischemic stroke due to large-vessel occlusion who receive endovascular thrombectomy, more than two-thirds nevertheless have a disabled final outcome. Restoring blood flow yields incomplete recoveries because some irreversible injury accrues before recanalization can be achieved and additional injury is generated by reperfusion itself. To fully eradicate stroke-related disability, complementary therapies are needed, including: bridging neuroprotection agents, which allow brain cells to tolerate ischemia until reperfusion is attained; reperfusion neuroprotection agents, which avert reperfusion injury; and neuroreparative agents, which promote postinjury reorganization of neurons and synapses. | 536 |
| 20 | Rheumatoid Arthritis in Adults: A Review
https://jamanetwork.com/journals/jama/fullarticle/2853931
This Review discusses the pathogenesis, epidemiology, risk factors, clinical presentation, diagnosis, treatment, and prognosis of rheumatoid arthritis (RA). | 451 |
